TEVIMBRA (tislelizumab)
Various solid tumors
ApprovedCommercial
Key Facts
About BeOne Medicines
BeOne Medicines is building the world's leading oncology company through scientific excellence and global reach, serving patients across 45+ countries with 12,000+ employees. The company has successfully transitioned from development to commercialization with approved therapies generating significant revenue. With substantial U.S. investment including $750M in R&D and a 400,000 square foot manufacturing facility, BeOne is positioned as a major player in global cancer treatment.
View full company profileTherapeutic Areas
Other Various solid tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| Individualized mRNA Cancer Immunotherapies | BioNTech | Phase 2/3 |
| IMA30X Series (ACTengine®) | Immatics | Pre-clinical |
| RP2 / RP2 + nivolumab | Replimune | Phase 1 |
| Bicycle Toxin Conjugates (BTCs) | Bicycle Therapeutics | Preclinical/Discovery |
| Bicycle Radio Conjugates (BRCs) | Bicycle Therapeutics | Preclinical/Discovery |
| Micvotabart pelidotin (MICVO) | Pyxis Oncology | Phase 1 |
| OST-tADC Platform | OS Therapies | Pre-clinical |